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Migraine Mediates the Influence of C677T MTHFR
Genotypes on Ischemic Stroke Risk With a
Stroke-Subtype Effect
Alessandro Pezzini, MD; Mario Grassi, PhD; Elisabetta Del Zotto, MD; Alessia Giossi, MD;
Roberto Monastero, MD, PhD; Giorgio Dalla Volta, MD; Silvana Archetti, MD; Paola Zavarise, MD;
Cecilia Camarda, MD; Roberto Gasparotti, MD; Mauro Magoni, MD;
Rosolino Camarda, MD; Alessandro Padovani, MD, PhD
Background and Purpose—The objective was to investigate the role of C677T MTHFR polymorphism in migraine
pathogenesis and in the migraine–ischemic stroke pathway.
Methods—A first genotype–migraine association study was conducted on 100 patients with migraine with aura (MA), 106
with migraine without aura (MO), and 105 subjects without migraine, which provided evidence in favor of association
of the TT677 MTHFR genotype with increased risk of MA compared with both control subjects (OR, 2.48; 95% CI, 1.11
to 5.58) and patients with MO (OR, 2.21; 95% CI, 1.01 to 4.82). Based on these findings, mediational models of the
genotype–migraine–stroke pathway were fitted on a group of 106 patients with spontaneous cervical artery dissection,
227 young patients whose ischemic stroke was unrelated to a spontaneous cervical artery dissection (noncervical artery
dissection), and 187 control subjects, and a genotype–migraine partial mediation model was selected.
Results—Both migraine and the TT genotype were more strongly associated to the subgroup of patients with spontaneous
cervical artery dissection (OR, 4.06; 95% CI, 1.63 to 10.02 for MA; OR, 5.45; 95% CI, 3.03 to 9.79 for MO; OR, 2.87;
95% CI, 1.45 to 5.68 for TT genotype) than to the subgroup of patients with noncervical artery dissection ischemic stroke
(OR, 2.22; 95% CI, 1.00 to 4.96 for MA; OR, 1.81; 95% CI, 1.02 to 3.22 for TT genotype) as compared with controls.
Conclusions—Migraine may act as mediator in the methylenetetrahydrofolate reductase–ischemic stroke pathway with a
more prominent effect in the subgroup of patients with spontaneous artery dissection. (Stroke. 2007;38:3145-3151.)
Key Words: genetics  migraine  risk factors  stroke in young adults
Despite lively debate in the past as to whether a migraine–stroke relation really exists, there is currently mounting
epidemiological evidence demonstrating that migraine in-
creases the risk of cerebral ischemia,1 which appears to be
higher among the young but may persist in the elderly,2,3 and
is also associated with subclinical brain white matter abnor-
malities.4,5 Migraine is known to run in families, suggesting a
condition that is at least partly regulated by genetics. It occurs
disproportionately more frequently in association with other
inherited disorders. Several large-scale epidemiologic studies
have confirmed that genetic factors play an important role in
migraine.6,7 More recently, the results of some genetic-
association studies have reinforced this assumption and sug-
gested the involvement of specific candidate genes. Among
them, the gene for methylenetetrahydrofolate reductase
(MTHFR) is currently the focus of much investigation. In
particular, the common single nucleotide polymorphism in
which cytosine (C) is replaced by thymidine (T ) at base
position 677, resulting in a thermolabile variant of the
enzyme with approximately half-normal activity, has been
reported to increase the risk of migraine with aura (MA) in
some case-control and cohort studies.8–12 Because of these
findings, despite some conflicting results,13,14 the C677T
MTHFR polymorphism seems to be a promising candidate to
migraine susceptibility. The polymorphism is also one of the
most extensively investigated candidates in cerebral ische-
mia. In the largest meta-analysis to date of studies examining
the association with ischemic stroke, Casas et al15 found an
increased risk among individuals homozygous for the T
allele, although the size of the effect seems to be modest
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compared with those of classic cardiovascular risk factors.
More recently, sparse reports indicated that the polymor-
phism might be more strongly associated to spontaneous
cervical artery dissection (sCAD),16,17 a vascular disorder for
which a specific relation with migraine has been suggest-
ed,18,19 than to other pathogenic stroke subtypes, thus leading
to the hypothesis of a differential influence on the risk of
cerebral ischemia.
Taken together, these findings prompt to speculate on the
existence of a relationship between this genetic variant and
migraine on stroke occurrence. Because both the C677T
MTHFR polymorphism and migraine are closely related to
ischemic stroke risk, and because the C677T MTHFR poly-
morphism could influence migraine susceptibility, we hy-
pothesized that the 2 factors might work together in the
pathogenic process leading to cerebral ischemia, and might
confer a higher disease risk.
We therefore performed 2 independent analyses in which
we genotyped the C677T MTHFR polymorphism in patients
with migraine and patients with ischemic stroke. First, to
investigate associations with migraine subtypes, we studied a
series of patients with MA, patients with migraine without
aura (MO), and control subjects. Second, to determine
whether genotype–migraine association may have an influ-
ence on the risk of stroke as a whole and on individual stroke
subtypes, we studied a series of well-phenotyped ischemic
stroke and control subjects.
Subjects and Methods
The study was approved by the local Ethics Committee. Informed
consent was provided by all study participants.
Study Population
Genotype–Migraine Association Study
To test the hypothesis of an association between the C677T MTHFR
genotypes and migraine, we considered a group of unrelated mi-
graine patients and control subjects, recruited from July 2005 to
September 2006. Migraine cases were selected from those consecu-
tively referred for outpatient examination of headache at the Head-
ache Center of the Istituto Clinico Citta` di Brescia, Brescia, and the
2 subtypes (MA and MO) frequency matched. Control subjects,
taken from the hospital staff, were included if they had no personal
history of headache, matched migraine cases by sex and age (in
3-year bands), and were from the same geographical area and ethnic
background.
Genotype–Migraine Mediation Study
The hypothesis of a mediational effect of the C677T MTHFR
genotypes via migraine on the risk of ischemic stroke was explored
in a case-control analysis including a group of unrelated patients
consecutively admitted to the Department of Neurology of the
University Hospital of Brescia between January 1999 and September
2006 and a group of control subjects. Because of the higher
prevalence of migraine as well as of the 677TT MTHFR genotype in
the subgroup of patients with cervical artery dissection as compared
with other stroke subtypes observed in previous studies,16–19 the
following 2 pathogenic subgroups of patients were selected: patients
with sCAD and patients with first-ever acute ischemic stroke
occurring before the age of 45, not related to a cervical artery
dissection (non-CAD). Dissections were classified as spontaneous
when occurring spontaneously or in association with a minor trauma,
and dichotomized in “single-vessel dissection” and “multiple-vessel
dissection,” according to the number of involved cervical arteries.
Patients with non-CAD ischemic stroke were those in whom a
diagnosis of CAD was excluded. A detailed description of the
standard diagnostic workup, as well as stroke subtype classification,
data collection, and risk factor definition have been presented
previously.16
Control Subjects
Subjects from the staff members of our hospital with no known
history of vascular disease aged younger than 45 years were invited
to participate in the study as controls. This group of control subjects
was different from the one selected for the genotype–migraine
association study. Both cases and controls were from the same
geographic area and ethnic background.
Assessment of Migraine History
Personal history of headache was assessed in all subjects by 4
investigators (E.D.Z., G.D.V., R.M., C.C.), during a face-to-face
interview, based on a semi-structured questionnaire.19 In stroke
cases, migraine was diagnosed retrospectively. History of migraine
before stroke occurrence was considered for the present analysis.
The diagnosis of MO and MA was made according to the diagnostic
criteria of the International Headache Society.20
Genetic Analysis
C677T MTHFR genotypes were determined according to the method
of Frosst et al,21 using polymerase chain reaction amplification and
restriction digestion with Hinf I to distinguish mutant from wild-type
alleles.
Statistical Analysis
To test the hypothesis of association between C677T MTHFR
genotypes and migraine subtypes, a bivariate (cross-tabulation)
analysis of the Genotype–Migraine Association Study data set was
performed. Because a potential TT677 MTHFR-migraine relation
was observed in this part of the study (that is, the 2 variables were
statistically associated), we applied a mediation modeling strategy to
the Genotype–Migraine Mediation Study data set to investigate the
hypothesis of a mediational effect of these 2 factors on the risk of
ischemic stroke. Actually, according to Baron and Kenny,22 a
mediator (the environment; here migraine, E) is an intermediate
variable that occurs in a causal pathway from an independent
variable (the genotype, G) to a dependent variable (the disease, D).
It determines variation in the dependent variable, and it is caused to
vary by the independent variable. Logically, G must temporally
precede E, so that E mediates G.
Two mathematical equations were fitted: a “disease equation,” in
which both G and E have a direct effect on D, and an “environment
equation,” in which G has a direct effect on E. Fixing specific
equation parameters equal to 0, 4 genotype–migraine mediation
models were obtained:23 (1) genotype–migraine partial mediation;
(2) genotype–migraine complete mediation; (3) genotype as proxy of
migraine and stroke; and (4) genotype–migraine overlapping (inde-
pendent) effects (Figure 1).
The modeling strategy assumed disease status (sCAD, non-CAD,
and controls) as outcome variable (D), migraine status (MO, MA,
and no migraine) as environment variable (E), and codominant
(ACC, BCT, CTT ), additive (0CC; 1CT; 2TT ), or
recessive (0CC or CT; 1TT ) C677T MTHFR coding as genotype
variable (G).
Accordingly, “disease equation” and “environment equation” were
categorical (multinomial) logistic regression models. Assessment of
mediation models without and with adjustment for covariates (age,
sex, smoking habit, hypertension, and hypercholesterolemia) was
performed. Diabetes mellitus was not entered in the final analysis as
covariate, because of the low frequency of this condition in the
present series. The regression models were fitted using maximum
likelihood estimates with robust standard errors computed by “sand-
wich” estimator.24 To compare these competing models, the Akaike
Information Criterion (Akaike Information Criterion2model
log-likelihood2number of model parameters), and the Bayesian
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Information Criterion (Bayesian Information Criterion2model
log-likelihoodlog(n)number of model parameters) were com-
puted. The selected model was the one minimizing either Akaike
Information Criterion or Bayesian Information Criterion.25 The
regression parameter estimates were re-expressed as ORs, and 95%
CIs using robust standard errors. Direct, indirect, and total ORs
effects of genotype on disease risk were computed from maximum
likelihood estimates, as proposed by Huang et al.26 Probability
values of the test z (parameter estimate/standard error) were per-
formed to test the null effect (OR1) across groups. The signifi-
cance level was set at P0.05 (2-sided). Multivariate modeling were
performed by Mplus 4.1 software (www.statmodel.com), whereas
bivariate statistics (2 testing for Hardy-Weinberg), equilibrium,
heterogeneity, and trend with probability values (computed by
Monte Carlo approximation method) were performed by Stata 9
software (www.stata.com).
Results
Genotype–Migraine Association Study
The study group consisted of 102 patients with MA (mean
age, 34.710.2 years; 68% women), 106 with MO (mean
age, 33.68.6 years; 72.6% women), and 105 subjects
without migraine (mean age, 34.47.4 years; 63.8% women).
Because DNA could not be amplified in 2 patients with MA,
data from 100 individuals were entered into the final analysis.
No migraine patient had personal history of stroke.
Genotype frequencies did not differed significantly from
those predicted by the Hardy-Weinberg equilibrium (2
[df]0.963; P0.326)1 within all the subgroups. There were
no significant differences in the TT677 MTHFR genotype
distribution between patients with MO and control subjects
(OR, 1.13; 95% CI, 0.48 to 2.66). In contrast, a significant
difference was observed between patients with MA and
control subjects (OR, 2.48; 95% CI, 1.11 to 5.58), as well as
between patients with MA and patients with MO (OR, 2.21;
95% CI, 1.01 to 4.82), in both cases because of an overrep-
resentation of the TT genotype in the subgroup of patients
with MA. The frequency of the T allele was also significantly
higher in the group of patients with MA than in the other 2
groups (OR, 1.46; 95% CI, 0.98 to 2.18 as compared with
patients with MO; OR, 1.50; 95% CI, 1.01 to 2.24 as
compared with control subjects; Table 1).
Genotype–Migraine Mediation Study
The study population consisted of 107 patients with sCAD
(confirmed by MRI/MRA [n46], digital subtraction angiog-
raphy [n17], or both [n44]), 81 (75.7%) with ischemic
stroke, 232 patients with non-CAD ischemic stroke, and 187
control subjects. Because DNA could not be amplified in 6
patients, the group of cases was composed of 106 patients
with sCAD (16 with multiple-vessel dissection) and 227
patients with non-CAD ischemic stroke. Demographic char-
acteristics and prevalence of selected risk factors are present-
ed in Table 2. Patients with non-CAD ischemic stroke more
often had hypertension and hypercholesterolemia, and were
more often smokers compared with control subjects. Patients
with sCAD more often had hypertension than control sub-
jects. A history of migraine was diagnosed more frequently in
the subgroup of patients with sCAD (n57, 53.7%) than in
the subgroup of patients with non-CAD ischemic stroke
(n55, 24.2%) and the group of control subjects (n34,
G D
E
G D
E
G D
E
G D
E
Figure 1. Genotype–migraine mediation
models. Ggenotype (C677T MTHFR);
Eenvironment (migraine); Ddisease
(stroke). (1) Genotype–migraine partial
mediation; (2) genotype–migraine com-
plete mediation; (3) genotype as proxy
of migraine and stroke; (4) genotype–
migraine independent effects.
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18.2%). Allele frequencies were in Hardy-Weinberg equilib-
rium (2 [df]1.242; P0.286)1 within the study subgroups.
Both the TT677 MTHFR genotype and the T allele were more
represented in the subgroup of patients with sCAD (n32,
30.2%; n109, 51.4%) than in the other 2 subgroups (n49,
21.6% and n210, 46.3% in patients with non-CAD ischemic
stroke; n27, 14.5%, and n141, 37.7% in the group of
control subjects).
Akaike Information Criterion index signed the “C677T
MTHFR and migraine partial mediation model” (model 1,
Figure 1) for codominant and additive (“counting alleles”)
genotype coding, whereas Bayesian Information Criterion
index signed “C677T MTHFR and migraine independent
effects model” (model 4, Figure 1) for all genotype coding.
Because model 1 had the highest log-likelihood in all coding
systems, and in the genotype–migraine association study we
signed a statistically significant association between genotype
and migraine, this model was selected as the best in predict-
ing the effect of C677T MTHFR genotype and migraine on
stroke risk (data not shown).
Direct effects estimates, re-expressed as ORs, of the
“environmental equation” and “disease equation” of the
selected model considering codominant genotype coding are
displayed in Table 3. The 677TT MTHFR genotype was
significantly more represented in the subgroup of patients
with MA as compared with subjects without migraine (OR,
2.28; 95% CI, 1.00 to 5.21), and as compared with patients
with MO (OR, 2.53; 95% CI, 1.06 to 6.02), whereas the
comparison between patients with MO and subjects without
migraine gave no significant differences (Table 3, top).
Patients with MA had4-fold risk for development of sCAD
(OR, 4.06; 95% CI, 1.63 to 10.02), and 2-fold risk for
Table 1. Frequency Distribution, Bivariate ORs (95% CI) of the C677T MTHFR Genotypes, and C677T MTHFR Alleles According to
Migraine Subtypes in the Genotype–Migraine Association Study
MO
(n106)
MA
(n100)
No Migraine
(n105)
MO vs No Migraine MA vs No Migraine MA vs MO
OR 95% CI OR 95% CI OR 95% CI
C677T MTHFR Genotypes
CC 42 (39.6) 33 (33.0) 41 (39.0) 1 1 1
CT 49 (46.2) 41 (41.0) 51 (48.6) 0.94 0.52–1.68 1.00 0.54–1.85 1.06 0.57–1.97
TT 15 (14.2) 26 (26.0) 13 (12.4) 1.13 0.48–2.66 2.48 1.11–5.58 2.21 1.01–4.82
C677T MTHFR Alleles
C 133 (62.7) 107 (53.5) 133 (63.3) 1 1 1
T 79 (37.3) 93 (46.5) 77 (36.7) 1.03 0.69–1.53 1.50 1.01–2.24 1.46 0.98–2.18
Table 2. Demographics and Cardiovascular Risk Factors Profiles in Patients with sCAD, Patients With Non-CAD
Ischemic Stroke, and Control Subjects
Characteristic
sCAD (n106)
meanSD
N -CAD Ischemic Stroke (n227)
meanSD
Control Subjects (n187)
meanSD P (MC)
Age, y 42.910.2 34.97.8 36.47.5 0.001
n (%) n (%) n (%)
Male 52 (49.0) 122 (53.4) 99 (52.9) 0.751
Current smokers 34 (32.0) 109 (48.0) 47 (25.1) 0.001
Hypertension 32 (30.2) 40 (17.6) 13 (6.9) 0.001
Diabetes mellitus 4 (3.8) 8 (3.5) 7 (3.7) 0.995
Hypercholesterolemia 29 (27.4) 65 (28.6) 36 (19.2) 0.060
Personal history of migraine 0.001
No migraine 49 (46.2) 169 (76.4) 153 (81.8)
MO 44 (41.5) 31 (13.7) 25 (13.4)
MA 13 (12.3) 24 (10.6) 9 (4.8)
C677T MTHFR genotype frequency 0.011
CC 29 (27.3) 66 (29.1) 73 (39.0)
CT 45 (42.5) 112 (49.3) 87 (46.5)
TT 32 (30.2) 49 (21.6) 27 (14.5)
C677T MTHFR allele frequency 0.003
C 103 (48.6) 244 (53.7) 233 (62.3)
T 109 (51.4) 210 (46.3) 141 (37.7)
P values (MC) are P values of ANOVA F test or 2 tests (2-tailed) for the 23 tables (df2) and 33 tables (df4) computed by Monte Carlo
approximation method.
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development of non-CAD ischemic stroke (OR, 2.22; 95%
CI, 1.00 to 4.96) compared with control subjects. A history of
MO conferred a 5-fold risk of sCAD (OR, 5.01; 95% CI, 2.86
to 8.77) as compared with non-CAD ischemic stroke, and a
5.5-fold risk (OR, 5.45; 95% CI, 3.03 to 9.79) as compared
with control subjects (Table 3, middle). The TT677 MTHFR
genotype was associated with 3-fold risk of sCAD (OR,
2.87; 95% CI, 1.45 to 5.68) and 2-fold risk of non-CAD
ischemic stroke (OR, 1.81; 95% CI, 1.02 to 3.22) in compar-
ison with control subjects. No significant difference in
genotype distribution was observed between the subgroup of
patients with sCAD and the subgroup of patients with
non-CAD ischemic stroke (Table 3, bottom).
These ORs were essentially unchanged when adjusted for
potential confounders including age, sex, hypertension,
smoking, and hypercholesterolemia (data not shown). Sum-
ming the direct effect of C677MTHFR gene with the indirect
effect via migraine, the estimated total effect of the TT-ge-
notype was 3.38 on the risk of sCAD, and 1.93 on the risk of
non-CAD ischemic stroke, as compared with control subjects.
The estimated increase in percentage of log–OR attributable
to mediation effect were 16% and 6%, respectively.
The evidence of a role of migraine in mediating the effect
of the TT677 MTHFR genotype on the risk of sCAD
prompted to speculate a dose-dependent influence of these 2
variables on clinical phenotype. Actually, the prevalence of
those with migraines carrying the TT677 MTHFR genotype
turned out to be higher among patients with multiple-vessel
dissection (3/16; 18.8%) than among those with single-vessel
dissection (12/90; 13.3%) and control subjects (5/187; 2.7%),
and the log–odds trend was statistically significant (2 [df]
for log–odds trend11.2; P 0.0008; Figure 2).
Discussion
Migraine and ischemic stroke are considered the end pheno-
type of polygenic disorders reflecting the influence of several
genetic loci modulating different pathophysiological pro-
cesses. Thus, it is reasonable to hypothesize that certain genes
might have an effect on both diseases and influence their
relation. At what levels in the migraine–stroke pathway these
genetic influences might be operating to increase the propen-
sity to cerebral ischemia and whether such effects might vary
according to different stroke subtypes are important and still
poorly investigated aspects of stroke pathogenesis. The re-
sults of our study put emphasis on the possibility to identify
some of these genetic susceptibility factors.
First, the present analysis demonstrates that subjects with
migraine, particularly MA, have an increased prevalence of
Table 3. Maximum Likelihood Estimates of Direct Effects Re-expressed as ORs (95% CI) in the
Environmental Equation (Top) and in the Disease Equation (Bottom) of the Selected C677T MTHFR and
Migraine Partial Mediation Model Using Codominant Genotype Coding
MA vs No Migraine MO vs No Migraine MA vs MO
OR 95% CI OR 95% CI OR 95% CI
C677T MTHFR genotypes
CC 1 1 1
CT 1.14 0.54–2.42 0.78 0.47–1.29 1.42 0.62–3.23
TT 2.28 1.00–5.21 1.25 0.68–2.28 2.53 1.06–6.02
sCAD vs Non-CAD sCAD vs Controls Non-CAD vs Controls
OR 95% CI OR 95% CI OR 95% CI
Personal history of migraine
No migraine 1 1 1
MO 5.01 2.86–8.77 5.45 3.03–9.79 1.19 0.62–1.91
MA 1.83 0.87–3.85 4.06 1.63–10.2 2.22 1.00–4.96
C677T MTHFR genotypes
CC 1 1 1
CT 1.03 0.87–3.85 1.36 0.76–2.44 1.32 0.86–2.03
TT 1.59 0.84–2.99 2.87 1.45–5.68 1.81 1.02–3.22
ORs of C677T MTHFR genotypes are adjusted for migraine status. ORs of migraine status are adjusted for C677T MTHFR genotypes.
Because history of migraine was unknown in 3 patients from the subgroup with non-CAD ischemic stroke, estimated values were
obtained from 224 subjects.
0
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Figure 2. OddsPr (TT genotype and any migraine)/Pr (other-
wise) for the subgroup of patients with single-vessel sCAD, the
subgroup of patients with multiple-vessel sCAD, and the group
of control subjects.
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the homozygous TT genotype and of the T allele of the C677T
MTHFR polymorphism. These findings confirm previous
evidence in favor of a direct contributory role of MTHFR as
a migraine gene.10–14
Second, a further confirmatory finding was that personal
history of migraine is associated with increased risk of
cerebral ischemia and the risk is strikingly different according
to aura status.1
Third, although the existence of a direct genotype–stroke
relation is likely, our results suggest that MTHFR contributes
to increase the risk of ischemic stroke at least in part through
its effect on migraine. In this regard, migraine should be
considered an intermediate factor in the complex pathway
from MTHFR to ischemic stroke, which mediates the effects
of genotype, and may explain how the C677T MTHFR
polymorphism works to influence ischemic stroke. If we look
at this relation another way, the C677T MTHFR poly-
morphism may be one of the hitherto unknown factors linking
migraine to cerebral ischemia.
Forth, an additional observation of the present study is the
finding of a stroke subtype-dependency for the triangular
MTHFR–migraine–stroke relation. In particular, stronger risk
effects of genotype and migraine were found in the subgroup
of patients with sCAD as compared with other pathogenic
subtypes. The finding that the 2 factors are more represented
in the subgroup of patients with multiple-vessel sCAD than in
the subgroup of those with single-vessel sCAD, although
statistically unstable because of the low frequencies in each
category, indirectly reinforces such an observation. All these
data confirm previous observations on the putative role of
both migraine and C677T MTHFR polymorphism in the
pathogenesis of sCAD,16–19 but also extends such findings,
pointing toward a mediational genotype–environmental ef-
fect between the 2 conditions on disease occurrence.
The biological links by which migraine may act as an
intermediate factor in the relation between the C677T
MTHFR polymorphism and ischemic stroke are likely to be
complex and currently speculative. The gene is a plausible
candidate in the migraine–stroke relation. Many studies using
animal models and human subjects have demonstrated that it
is actively involved in the maintaining of the normal homeo-
static properties of vascular endothelium, which include
endothelium-dependent regulation of vascular tone, hemosta-
sis, and inflammation, a process relevant to both cortical
spreading depression, the presumed mechanism behind mi-
graine aura, and cerebral ischemia.27,28 Furthermore,
homocysteine-related dysfunction of the vascular endotheli-
um has been demonstrated to activate trigeminal fibers,
leading to an inflammatory reaction in the meninges and a
dilation of the large cerebral vessels. This mechanism is
thought to participate in the head pain associated with
migraine.29,30
Our study has several strengths, including the relatively
large number of subjects in each subgroup, the use of a
standardized questionnaire and diagnostic workup, and the
homogeneous nature of the study group, which may reduce
confounding. Nevertheless, several limitations should be
pointed out. Because of the retrospective migraine ascertain-
ment in our stroke patients, a recall bias cannot be theoreti-
cally excluded. However, because cases were unaware of the
hypothesis undergoing study, there is no reason why they
should have reported migraine symptoms more completely
than controls. An interviewer bias is also unlikely, because of
the use of a structured questionnaire for the diagnosis of
migraine. Furthermore, even taking into account such poten-
tial biases, we have no reason to believe that they have any
influence on genotype distribution in each specific subgroup.
An additional limitation is that we had no information
regarding the duration of migraine or frequency of migraine
attacks in our series. Any consideration on differential effects
according to migraine activity is, therefore, speculative based
on our data. No detailed information is also available on the
use of migraine-specific drugs. Because of the known vaso-
constrictive effect of these molecules (particularly, ergota-
mines),31 they might be theoretically associated with in-
creased risk of cerebral ischemic events. The safety profiles
of these compounds as well as their use by both subjects with
MO and subjects with MA, however, make this an unlikely
explanation of our findings. Finally, although we adjusted for
major potential confounders, residual confounding is possible
given the observational design of the study.
In conclusion, our findings reinforce the assumption that
specific hereditary factors contribute to migraine–stroke sus-
ceptibility, with the relative contribution of these genetic
determinants different for MA as compared with MO. In
particular, they indicate that the C677T MTHFR polymor-
phism is associated with MA, that its predisposing influence
on the risk of ischemic stroke is in part mediated by migraine,
and that the magnitude of this effect is greater for arterial
dissection than for other stroke mechanisms. The study
indirectly supports the theory that genetic loci related to
homeostatic properties of vascular endothelium are promising
candidate sites in the complex migraine–stroke pathway.
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